Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 2, 1997, Pages 104-114

  Bucher, Heiner C ^a,c   Griffith, Lauren ^a   Guyatt, Gordon H ^a   Opravil, Milos ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c KANTONSSPITAL BASEL   (Switzerland)

Author keywords

Aerosolized pentamidine; Dapsone; HIV infection; Meta analysis; Pneumocystis carinii pneumonia; Primary prevention; Pyrimethamine; Toxoplasma encephalitis; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; PYRIMETHAMINE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS CARINII; TOXOPLASMA; TOXOPLASMA GONDII;

EID: 0030853402     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199706010-00002     Document Type: Article

References (37)

1. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-9.
2. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
3. Leoung GS, Feigal DW, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: The San Francisco Community Prophylaxis Trial. N Engl J Med 1990;323:769-75.
4. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1842-8.
5. Schneider MME, Hoepelman AIM, Karel J, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
6. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-11.
7. Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993;328:1514-1420.
8. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995;20:531-41.
9. Schwartländer B, Horsburgh CR, Hamouda O, Skarabis H, Koch MA. Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. AIDS 1992;6:413-420.
10. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994;271:1083-7.
11. Lundgren JD, Philips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92.
12. Chalmers TC, Smith H, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981; 2:31-49.
13. Stellini R, Castelnuovo F, Paraninfo G, Scalzini A. Trimethoprim-sulfa-methoxazole versus pyrimethamine in the primary prophylaxis of toxoplasmic encephalitis in HIV positive patients: preliminary results of a randomized prospective study [abstract PO-B10-1505]. Program and abstracts of the Ninth International Conference an AIDS. Berlin, Germany, 1993.
14. Tocchetti A, Tambini R, Allegro A, Longoni E, Rinaldi E. Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. AIDS 1994;8:272-4.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
16. Rothman KJ. Modern epidemiology. Boston: Little, Brown and Co., 1986.
17. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.
18. SAS Institute, Inc. SAS guide for personal computers, version 6.03. Cary, NC: SAS Institute, Inc., 1988.
19. May T, Beuscart C, Reynes J, et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. J Acquir Immune Defic Syndr 1994; 7:457-62.
20. Nielsen TL, Jensen BN, Nelsing S, Mathiesen LR, Skinhøj P, Nielsen JO. Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Scand J Infect Dis 1995;27:217-20.
21. Michelet C, Raffi F, Besnier JM, et al. Cotrimoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia [abstract 1071]. Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993:315.
22. Smith DE, Hills DA, Gazzard BG. Patient tolerance of nebulized pentamidine or cotrimoxazole as secondary prophylaxis for Pneumocystis carinii pneumonia. AIDS 1992;6:1044-45.
23. Rozenbaum W, Tavares M, Navarette MS, Gharakhanian S, Cardon B, Lebrette MG. Evaluation of trimethoprim sulfamethoxazole vs aerosolized pentamidine with concomitant onset of zidovudine in primary Pneumocystis carinii pneumonia prophylaxis [abstract W.B. 2247]. Program and abstracts of the Seventh International Conference on AIDS. Amsterdam, June 16-21, 1991:243.
24. Rizzardi GP, Lazzarin A, Musicco M, et al. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. J Infect 1996;32:123-31.
25. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992;6:1169-74.
26. Torres RA, Barr M, Thorn M, et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993; 95:573-83.
27. Salmon-Ceron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995;172:656-64.
28. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced HIV infection. N Engl J Med 1995;332:693-99.
29. Antinori A, Murri R, Ammassari A, De Luca A, Linzalone A, Cmgolani A. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995;9:1343-50.
30. Mallolas J, Zamora L, Gatell JM, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993;7:59-64.
31. Podzamczer D, Santín M, Jiménez J, et al. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 1993;7:501-6.
32. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim-sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1992;5:341-7.
33. Podzamczer D, Salazar A, Jiménez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;122:755-61.
34. Sirera G, Clotet B, Romeu J, Raventos A, Gomez M, Paredes R. A randomized study of primary prophylaxis of Pneumocystis carinii pneumonia and cerebral toxoplasmosis with twice weekly dapsone-pyrimethamine versus thrice weekly co-trimoxazole [abstract 295]. Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections. Washington, DC, January 29-February 2, 1995.
35. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9.
36. Bozzette SA, Forthal D, Sattler FR, et al. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. Am J Med 1995;98:177-82.
37. Nguyen MT, Weiss PJ, Wallace MR. Two day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995;9:573-5.